blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1180102

EP1180102 - MUTUAL PRODRUGS OF AMLODIPINE AND ATORVASTATIN [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.04.2005
Database last updated on 26.06.2024
Most recent event   Tooltip15.04.2005No opposition filed within time limitpublished on 01.06.2005  [2005/22]
Applicant(s)For all designated states
Pfizer Products Inc.
Eastern Point Road
Groton, CT 06340 / US
[N/P]
Former [2002/08]For all designated states
Pfizer Products Inc.
Eastern Point Road
Groton, Connecticut 06340 / US
Inventor(s)01 / CHANG, George
Pfizer Central Research, Eastern Point Road
Groton, CT 06340 / US
02 / HAMANAKA, Ernest Seiichi
Pfizer Central Research, Eastern Point Road
Groton, CT 06340 / US
03 / LAMATTINA, John Lawrence
Pfizer Central Research, Eastern Point Road
Groton, CT 06340 / US
 [2002/08]
Representative(s)Ruddock, Keith Stephen, et al
Pfizer
ATTENTION: ADDRESS INACTIVE - USE ASS-NR - CDR / FR
[N/P]
Former [2005/13]Ruddock, Keith Stephen, et al
Pfizer Limited European Patents Department, Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
Former [2002/08]Sewell, Richard Charles
UK Patent Department, Pfizer Limited, Ramsgate Road
Sandwich, Kent CT13 9NJ / GB
Application number, filing date00911145.120.03.2000
[2002/08]
WO2000IB00313
Priority number, dateUS19990136608P27.05.1999         Original published format: US 136608 P
[2002/08]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO0073298
Date:07.12.2000
Language:EN
[2000/49]
Type: A1 Application with search report 
No.:EP1180102
Date:20.02.2002
Language:EN
The application published by WIPO in one of the EPO official languages on 07.12.2000 takes the place of the publication of the European patent application.
[2002/08]
Type: B1 Patent specification 
No.:EP1180102
Date:09.06.2004
Language:EN
[2004/24]
Type: B9 Corrected patent specification 
No.:EP1180102
Date:02.03.2005
[2005/09]
Search report(s)International search report - published on:EP07.12.2000
ClassificationIPC:C07D401/12, C07D405/14, A61K31/44, A61P9/10
[2002/08]
CPC:
C07D401/12 (EP,US); C07D405/14 (EP,KR,US); A61K47/55 (EP,US);
A61P3/06 (EP); A61P9/10 (EP); A61P9/12 (EP)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2002/08]
Extension statesAL15.11.2001
LT15.11.2001
LV15.11.2001
MK15.11.2001
RO15.11.2001
SI15.11.2001
TitleGerman:GEGENSEITIGE PRODRUGS VON AMLOPIDIN UND ATORVASTATIN[2002/08]
English:MUTUAL PRODRUGS OF AMLODIPINE AND ATORVASTATIN[2002/08]
French:PROMEDICAMENTS COMMUNS D'AMLODIPINE ET D'ATORVASTATINE[2002/08]
Entry into regional phase15.11.2001National basic fee paid 
15.11.2001Designation fee(s) paid 
15.11.2001Examination fee paid 
Examination procedure07.08.2000Request for preliminary examination filed
International Preliminary Examining Authority: EP
15.11.2001Amendment by applicant (claims and/or description)
15.11.2001Examination requested  [2002/08]
25.09.2002Despatch of a communication from the examining division (Time limit: M04)
22.01.2003Reply to a communication from the examining division
08.12.2003Communication of intention to grant the patent
08.04.2004Fee for grant paid
08.04.2004Fee for publishing/printing paid
Opposition(s)10.03.2005No opposition filed within time limit [2005/22]
Fees paidRenewal fee
21.03.2002Renewal fee patent year 03
24.01.2003Renewal fee patent year 04
19.12.2003Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[DXA]WO9911259  (PFIZER [US], et al) [DX] 1 * page 21 - page 36 * * claim - *[A] 2-5,11-47
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.